Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 19, Art. 89 (pp. 1254-1264)    |    2018       

»

The effect of extent of glioblastoma resection on the progression-free period duration.

Gulyaev D.A., Krasnoshlyk P.V., Lahina YU.S., Petrov A.A.

Federal State Budgetary Institution V.A. Almazov National Medical Research Center, Saint Petersburg

Brief summary

The aim of our research is studying the effect of the radical removal of glioblastoma hyperintense on T2 Flair image area on the progression-free period duration. Now it is customary to refer to glioblastoma not only a hyperintense site on T1 post-contrast images, but also a zone of hyperintensive T2 Flair signal with peritumoral located, previously considered the area of perifocal oedema. Our work is based on a series of 19 observations of patients between the ages of 18 and 79, whose average age was 47.29 years; the sexual ratio was 1: 1.37 in favor of women who had been operated on for intracerebral high-grade glial tumors Sawaya II-III, using intraoperative electrophysiological monitoring and neuronavigation equipment. Patients with a preserved hyperintense signal in the T2 image detected by MRT, have no significant differences in life expectancy, regardless of the extent of the removal of this zone, but a significantly lower duration of the progression-free period compared to the group of observations of total tumor removal with the Flair zone. Thus, the zone of perifocal changes has great importance in predicting the disease prognosis, which may be related to its cellular composition, so it is important to research cell composition of the perifocal zone.


Key words

IDH mutation, MGMT gene promoter, hyperintense T2 Flair signal zone, extent of resection, prognosis.

Reference list

1. Louis DN, Ohgaki H, Wiestler OD, et al. World Health Organization Histological Classification of Tumors of the Central Nervous System. Lyon: International Agency for Research on Cancer; 2016


2. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73 CrossRef Medline


3. Jain R, Poisson LM, Gutman D, et al. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology 2014;272:484 -93 CrossRef Medline


4. Kotrotsou A, Elakkad A, Sun J, et al. Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. J Neurooncol. 2018 Aug;139(1):125-133. doi: 10.1007/s11060-018-2850-4.


5. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190-198, 2001


6. Lang FF, Sawaya R, Suki D, McCutcheon IE, Hess KR: Glioblastoma resection. J Neurosurg 116:1166-1167, author reply 1167-1168, 2012


7. Li YM, Suki D, Hess K, et al. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 2016;124:977-88 CrossRef Medline


8. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS: An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3-8, 2011


9. Eidel O, Burth S, Neumann JO, et al. Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS One 2017;12:e0169292 CrossRef Medline


10. Glover GH, Law CS. Spiral-in/out BOLD fMRI for increased SNR and reduced susceptibility artifacts. Magn Reson Med. 2001;46:515


11. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma Multiforme and Anaplastic Astrocytoma Cancer 56:1106-111 I, 1985.


12. Chow D, Chang P, Weinberg BD, Bota DA, Grinband J, Filippi CG. Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. AJR Am J Roentgenol. 2018; 210(1):30-8. Epub 2017/10/06. https://doi.org/10.2214/AJR.17.18754 PMID: 28981352


13. Lin C.L, Lieu A.S, Lee K.S, Yang Y.H.C, Kuo T.H, Hung M.H, Loh J.K, Yen C.P, Chang C.Z, Howng S.L, Hwang S.L. The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme Surgical Neurology Volume 60, Issue 5, November 2003, Pages 402-406


14. Quigley R. M., C. Post, Ehrlich G. Some speculation on the origin of glioblastoma. Neurosurg Rev (2007) 30:16-21 DOI 10.1007/s10143-006-0048-2


15. Friedlein K., Bozhkov Y., Hore N., Merkel A., Sommer B., Brandner S., Buchfelder M, Savaskan N. E., Eypoglu I.Y. A new functional classification system (FGA/B) with prognostic value for glioma patients. Scientific Reports, July 2015


16. Abreu F.B., Gallagher T. L, Liu E. Z., Tsongalis G. J. Determining methylation status of methylguanine DNA methyl transferase (MGMT) from formalin-fixed, paraffin embedded tumor tissue. MethodsX 1 (2014) 42-48.


17. Holodny AI, Makeyev S, Beattie BJ, et al. Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging. AJNR Am J Neuroradiol 2010;31:1042-48 doi:10.3174/ajnr.A1989 pmid:20150307


18. Iliadis, G., Selviaridis, P., Kalogera-Fountzila, A. et al. The Importance of Tumor Volume in the Prognosis of Patients with Glioblastoma Strahlenther Onkol (2009) 185: 743. https://doi.org/10.1007/s00066-009-2015-7


19. Lasocki A, Gaillard F, Tacey M, et al. Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma. J Med Imaging Radiat Oncol 2016;60:66 -73 CrossRef Medline


20. Wilson CB: Glioblastoma: the past, the present, and the future. Clin Neurosurg 38:32-48, 1992